Healthcare Industry News: Lyrica
News Release - August 2, 2007
PTC Therapeutics Appoints Theresa Natalicchio as Senior Vice President of Marketing and SalesSOUTH PLAINFIELD, N.J., Aug. 2 (HSMN NewsFeed) -- PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focused on the discovery, development and commercialization of small-molecule drugs targeting post-transcriptional control mechanisms, today announced that Theresa Natalicchio has been appointed as Senior Vice President of Marketing and Sales. In this role, she will be responsible for all commercialization aspects of PTC's programs.
"We are excited to welcome Theresa to our management team," said Stuart Peltz, Ph.D., President and CEO of PTC Therapeutics, Inc. "As we begin commercialization planning for our products, we look forward to leveraging Theresa's extensive experience in the creation of successful product launch and marketing campaigns."
"PTC's drug discovery platform has the potential to address a broad range of genetic disorders, as well as many cancers and infectious diseases. I have been impressed with the company's unique and innovative scientific focus and look forward to working with the PTC team to deliver these potential breakthrough treatments to patients who urgently need them," commented Ms. Natalicchio.
Ms. Natalicchio comes to PTC with 25 years of product marketing experience at Pfizer. Inc. where she most recently held the position of Vice President of the Marketing Centers of Excellence overseeing consumer strategy, public relations, e-marketing, media, agency management, multicultural marketing and relationship marketing for Pfizer's portfolio of US pharmaceutical products. Ms. Natalicchio began her career as a Market Research Analyst, advancing quickly into roles of increasing responsibility where she was primarily responsible for launch of blockbuster products such as Procardia XL®, Zithromax®, Zyrtec®, Viagra® and Lyrica®. Her previous roles have included U.S. and worldwide marketing, leading businesses focused on multiple therapeutic areas including arthritis, anti-infective, urology and women's health.
About PTC Therapeutics, Inc.
PTC is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary, small-molecule drugs that target post-transcriptional control processes. Post- transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC's internally-discovered pipeline addresses multiple therapeutic areas, including genetic disorders, oncology and infectious diseases. In addition, PTC has developed proprietary technologies and extensive knowledge of post- transcriptional control processes that it applies in its drug discovery and development activities, including the Gene Expression Modulation by Small- molecules (GEMS) technology platform, which has been the basis for collaborations with leading pharmaceutical and biotechnology companies such as Pfizer, CV Therapeutics and Schering-Plough. For more information, visit the company's website, www.ptcbio.com.
Source: PTC Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.